Anti-Müllerian Hormone Predicts Menopause in HIV-Infected Women
Measuring anti-Müllerian hormone in HIV-infected women may enable clinicians to predict risk of early menopause.
HealthDay News — For HIV-infected women, anti-Müllerian hormone (AMH) is associated with age of menopause onset, according to a study published in the American Journal of Obstetrics & Gynecology.
Rebecca Scherzer, PhD, from the University of California, San Francisco, and colleagues examined the correlation between AMH and age of menopause onset in 2461 HIV-infected women. The authors identified factors associated with age at final menstrual period in multivariable normal mixture models for censored data.
The researchers found that even after multivariable adjustment for smoking, CD4 cell count, plasma HIV RNA, hepatitis C infection, and history of clinical AIDS, higher AMH at age 40 years correlated with later age at final menstrual period. There was a 1.5-year increase in the age at final menstrual period for each doubling of AMH.
The median age at final menstrual period varied from 45 to 52 years for those in the 10th and 90th percentiles of AMH, respectively. There were independent associations for smoking, hepatitis C infection, higher HIV RNA levels, and history of clinical AIDS with earlier age at final menstrual period.
"Measuring AMH in HIV-infected women may enable clinicians to predict risk of early menopause, and potentially implement individualized treatment plans to prevent menopause-related comorbidities and to aid in interpretation of symptoms," the authors write.
Two authors disclosed financial ties to the pharmaceutical and medical device industries.
Scherzer R, Greenblatt RM, Merhi ZO, et al. Use of antimüllerian hormone to predict the menopausal transition in HIV-infected women. Am J Obstet Gynecol. 2017;216:46.e1-46.e11. doi: 10.1016/j.ajog.2016.07.048